BEAM
Beam Therapeutics Inc.
There isn't enough reported data to score BEAM yet.
BEAM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
BEAM's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
BEAM PE Valuation
BEAM has no meaningful PE right now: it lost money over the past year.
BEAM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect BEAM's losses to grow, with revenue declining. However, they disagree widely on these estimates.
BEAM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.84 | +$3.59 |
| Q2 2026 | -$0.66 | +$3.84 |
| Q1 2026 | -$0.48 | +$4.13 |
| Q4 2025 | -$0.81 | +$3.77 |
| Q3 2025 | -$4.43 | -$2.85 |
| Q2 2025 | -$4.50 | -$2.87 |
| Q1 2025 | -$4.61 | -$3.01 |
| Q4 2024 | -$4.58 | -$2.86 |
BEAM is still losing money, but far less than before: $0.84 per share over the past year, against $7.05 at its worst in mid-2021.
BEAM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $307K | -97% |
| Q2 2026 | $490K | -94% |
| Q1 2026 | $31.7M | +325% |
| Q4 2025 | $114.1M | +280% |
| Q3 2025 | $9.7M | -32% |
| Q2 2025 | $8.5M | -28% |
| Q1 2025 | $7.5M | +0.8% |
| Q4 2024 | $30.1M | -90% |
BEAM's revenue is growing: $307,000 last quarter, down 97% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -46033% | -44726 points |
| Q2 2026 | -25827% | -24408 points |
| Q1 2026 | -338% | +1259 points |
| Q4 2025 | -15% | +317 points |
| Q3 2025 | -1308% | -561 points |
| Q2 2025 | -1419% | -528 points |
| Q1 2025 | -1597% | -192 points |
| Q4 2024 | -333% | -375 points |
BEAM's operating margin was −46033% last quarter, down 44726 points from the same quarter a year ago.
BEAM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$112M | -$25.5M |
| Q2 2026 | -$68.5M | +$11.1M |
| Q1 2026 | -$130.7M | -$23.8M |
| Q4 2025 | -$87M | -$7.7M |
| Q3 2025 | -$86.5M | +$3.2M |
| Q2 2025 | -$79.6M | +$5.4M |
| Q1 2025 | -$106.9M | -$4.8M |
| Q4 2024 | -$79.3M | -160% |
BEAM has burned cash in almost every quarter: −$398M over the past year, against −$352M the year before.
BEAM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +372K shares |
| 1 year | +2.1% | +2.1M shares |
| 3 years | +32% | +25.7M shares |
| 5 years | +58% | +38.3M shares |
| Available history | +241% | +74M shares |
BEAM has 105M diluted shares, up 2.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
BEAM Net Leverage
BEAM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
BEAM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.3 | Neutral |
| Stochastic | 36.5 | Neutral |
BEAM's weekly RSI is 44 (neutral) and its Stochastic is 37 (neutral).
BEAM PE vs Healthcare Sector
BEAM has no meaningful PE right now: it lost money over the past year.
BEAM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $25.0 | 3.7% below |
| 20 week MA | $26.9 | 11% below |
| 50 week MA | $27.8 | 14% below |
| 100 week MA | $25.0 | 3.7% below |
| 200 week MA | $26.7 | 10% below |
BEAM is in a downtrend: it's below all five of its weekly moving averages, and 10% below its 200-week average.
BEAM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $20.6 | $87.8 | +326% |
| 2021 | $87.8 | $86.5 | -1.5% |
| 2022 | $86.5 | $40.4 | -53% |
| 2023 | $40.4 | $27.2 | -33% |
| 2024 | $27.2 | $26.6 | -2.3% |
| 2025 | $26.6 | $28.0 | +5.2% |
| 2026 YTD | $28.0 | $24.0 | -14% |
BEAM's yearly returns have swung widely, from +326% in 2020 to −53% in 2022. It's down 14% so far in 2026.